Halozyme Therapeutics (HALO) Tops Q4 EPS by 11c
Tweet
Share
E-mailGet Alerts HALO Hot Sheet
Price: $69.62 +0.91%
Revenue Growth %: +23.1%
Financial Fact:
Total revenues: 31.85M
Today's EPS Names:
CBRS, MAYS, CRMT, More
Revenue Growth %: +23.1%
Financial Fact:
Total revenues: 31.85M
Today's EPS Names:
CBRS, MAYS, CRMT, More
Join SI Premium – FREE
Halozyme Therapeutics (NASDAQ: HALO) reported Q4 EPS of $0.03, $0.11 better than the analyst estimate of ($0.08). Revenue for the quarter came in at $52.2 million versus the consensus estimate of $42.06 million.
GUIDANCE:
Halozyme Therapeutics sees FY2016 revenue of $110-125 million, versus the consensus of $120.2 million.
For earnings history and earnings-related data on Halozyme Therapeutics (HALO) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Green Dot and CommerceOne shareholders approve acquisition deal
- After-Hours Stock Movers: FDX, CBRS, NKE
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
